Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps she is taking to improve the supply of elvanse.

We are aware of disruptions to the supply of medicines used for the management of attention deficit hyperactivity disorder (ADHD), primarily driven by issues which have resulted in capacity constraints at key manufacturing sites.

The National Patient Safety Alert to the National Health Service advises healthcare professionals on the management of patients during this time. We have well-established processes for managing and mitigating medicine supply issues, which involve working with the pharmaceutical industry, the Medicines and Healthcare products Regulatory Agency, NHS England, the devolved governments and others operating in the supply chain to help ensure patients have access to the treatments they need.

The Department has been working closely with manufacturers of all ADHD medicines and some issues have now been resolved, including Elvanse Adult 50 milligram and 70 milligram capsules. However, we know that there continue to be disruptions to the supply of some other medicines, including other presentations of Elvanse, which are expected to resolve in early 2024.